Inactive Instrument

Press Releases Peptonic Medical AB Nasdaq Stockholm

Equities

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

05-31	Peptonic Medical Secures European Patent for Treatment of Vulvodynia	MT
05-31	Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Peptonic Medical: Peptonic announces outcome in the rights issue and the directed issue	06-14	PU
Peptonic announces outcome in the rights issue and the directed issue	06-14	AQ
Peptonic Medical provides an operational update after the first 120 days with new CEO	06-11	AQ
Last day of trading with the unit rights in Peptonic	06-07	AQ
Peptonic Medical AB granted patent in Europe for relief of provoked vulvodynia in women. Product ready for launch.	05-31	AQ
The subscription period in Peptonic's rights issue of units starts today	05-28	AQ
Peptonic publishes prospectus in connection with rights issue of units	05-24	AQ
PEPTONIC medical : Interim report Jan-March 2024	05-23	PU
Peptonic Medical AB Announces Organizational Changes	05-21	AQ
The board of Peptonic has decided to carry out a directed issue of units consisting of shares and warrants of series TO5	05-19	AQ
PEPTONIC medical : Updated year end report Jan-Dec 2023	05-16	PU
PEPTONIC medical : Year end report Jan Dec 2023	05-16	PU
Jenni Björnulfson appointed as new CFO of Peptonic Medical	05-15	AQ
Warrants of series TO4 were subscribed to approximately 1.80 percent and Peptonic receives approximately SEK 0.1 million	05-07	AQ
The last day of trading with the warrants of series TO4 in PEPTONIC medical AB is today, April 26, 2024	04-26	AQ
The board of Peptonic resolves, subject to approval of the general meeting, on a rights issue of units of approximately SEK 61.4 million	04-16	AQ
The subscription price for the warrants of series TO4 in PEPTONIC medical AB has been determined to SEK 0.028 and the exercise period starts April 17, 2024	04-16	AQ
Peptonic Medical AB granted patent in the USA for treatment and prevention of yeast infections among women	04-15	AQ
Peptonic Medical AB strengthens its position in Europe through an exclusive distribution agreement for VagiVital and Vernivia in the Benelux region	04-02	AQ
Peptonic Medical AB announces that CFO is leaving for new challenges and that the company's financial infrastructure is strengthened	03-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Peptonic Medical AB Nasdaq Stockholm

Equities

Press Releases

Filters